Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsAntibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesMethotrexate for maintenance of remission in Crohn's diseaseMethotrexate for maintenance of remission in Crohn's diseaseVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseImmunogenicity of protein therapeutics: The key causes, consequences and challengesA dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseInfliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective studyCirculating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical responseThe immunotherapy of Alzheimer's diseaseClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseUnderstanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reductionCurrent status of biosimilars in the treatment of inflammatory bowel diseasesTherapeutic drug monitoring in inflammatory bowel diseaseUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Review article: anti-adhesion therapies for inflammatory bowel diseaseInfliximab-Related Infusion Reactions: Systematic ReviewVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Optimizing the use of biological therapy in patients with inflammatory bowel diseaseUse of the tumor necrosis factor-blockers for Crohn's diseaseExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesThe Role of Laboratory Tests in Crohn's DiseaseSevere and steroid-resistant Crohn's diseaseReview article: Infliximab therapy for inflammatory bowel disease--seven years onPredicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical ProteinsIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.Medical management of Crohn's disease: current therapy and recent advances.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case study.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
P2860
Q22242050-5AB8013A-BA1A-48F8-BE9C-FC77BAD080E7Q24185835-3C451A82-5CF8-4187-895C-F68B5FE8511AQ24194293-8AEA177B-2F33-4754-BA21-6B254D280ACDQ24240054-5D8D6BAF-4334-4EA8-BB3C-F4382A1A0014Q24630083-72B287BD-1AE9-42E5-BDAC-78A914B99BC1Q24633296-FB76D597-A1E0-42EA-8CFF-9C25839D30A2Q24680126-B7800C22-86F3-4683-BA47-2F523D911085Q24798468-60B14D81-C635-414F-BF65-24C28A2C37C5Q24799187-13A60363-B455-4CE7-AC98-916B4DFE1133Q24804900-39C1D00D-1D1B-4128-8168-A24766D96833Q24816557-E5B704F9-9A5B-4999-88A6-1AFDE28E9AA4Q26745721-CE0EA6A9-5036-4AC7-8C02-2575E12855E1Q26747193-C1F15EC6-3D47-4FAB-9081-51F01294E5D8Q26752950-D9ED2F7C-4B68-495A-8D15-2D46C04176BAQ26765350-560C753A-D9F7-45B8-BCBF-C7EF3512CF78Q26852729-D17DBE06-E94E-48F2-9804-601C6386F056Q26996946-68F228D5-E36C-484C-9266-43FC5A89F092Q26999705-3D02BDD0-9351-409F-A346-DC3673DCBCC7Q27013835-C4E9DDCA-6184-4F37-87F2-9E42D4C338B0Q27021612-81BA267D-8855-4487-BC65-142A0DE62915Q27025513-DC112C63-9894-4ACB-9013-0CB3B22EAFCDQ27030762-5BA68669-F86A-476D-8415-F5AA98F65B2DQ28066776-66EF81D8-0BE1-4672-8754-2E0849EE0C5CQ28075045-01FC41EE-A20B-443F-B076-A76B9A9488DBQ28266806-CBF4D138-1F43-41BA-8CB7-F73C2FBCB3FBQ28294134-C2934369-7DB1-4D26-835E-5A87FA57A82BQ28547255-F7C87858-B983-4E2B-8FD7-2EA96DDFE7D9Q30235581-680F4734-0A68-4B4A-926E-2F9C4DC8E49FQ30412650-FB0DD6C1-FC84-4EAA-9CAC-264362BDF977Q30444398-4201FE97-05EB-4636-A76A-4FEDD0F10654Q30450875-4A862397-0407-423C-BC43-D78011957A0AQ30675199-C4BEC9BA-658F-422C-A775-928FCE388858Q30725001-132E9BE6-946E-4823-ACBB-A6B13FB5A231Q30847784-AD3E269C-A28D-41F5-AAD1-2B0F53658F88Q30987208-8FA1DF34-184A-4AD9-A595-E309C6A22734Q30995889-6D5C4C09-AF87-4B1E-81C3-5D8334028284Q31085610-5D6AEF03-2B05-47C0-8784-438A3274E3A7Q31151474-C5CF96B3-E134-41F4-849E-0CEB9812EF5EQ33161260-80420812-62CB-43DE-A9A9-8A64FB57A90AQ33224048-E59237FB-B41F-4EBC-95B0-9C1AFF2C7E21
P2860
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
description
im Februar 2003 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2003
@uk
name
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@en
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@nl
type
label
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@en
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@nl
prefLabel
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@en
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@nl
P2093
P356
P1476
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
@en
P2093
An Carbonez
Filip Baert
Geert D' Haens
Maja Noman
Severine Vermeire
P304
P356
10.1056/NEJMOA020888
P407
P577
2003-02-13T00:00:00Z